https://www.ascopost.com/news/october-2021/aacr-cancer-progress-report-2021-showcases-50-years-of-advances-in-cancer-research-and-treatment/
https://ascopost.com/news/october-2021/aacr-cancer-progress-report-2021-showcases-50-years-of-advances-in-cancer-research-and-treatment/
https://www.ascopost.com/issues/october-10-2021/neoadjuvant-atezolizumab-under-study-in-mesothelioma/
https://ascopost.com/issues/october-10-2021/neoadjuvant-atezolizumab-under-study-in-mesothelioma/
https://www.ascopost.com/news/october-2021/fda-pipeline-recent-reviews-designations-applications-and-authorizations-in-the-oncology-space/
https://ascopost.com/news/october-2021/fda-pipeline-recent-reviews-designations-applications-and-authorizations-in-the-oncology-space/
https://www.ascopost.com/news/october-2021/axicabtagene-ciloleucel-for-adult-patients-with-primary-mediastinal-b-cell-lymphoma-real-world-outcomes/
https://ascopost.com/news/october-2021/axicabtagene-ciloleucel-for-adult-patients-with-primary-mediastinal-b-cell-lymphoma-real-world-outcomes/
https://www.ascopost.com/issues/september-25-2021/nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://ascopost.com/issues/september-25-2021/nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://www.ascopost.com/issues/september-25-2021/guideline-rapid-update-provides-new-direction-on-the-care-of-patients-with-residual-disease-in-locally-advanced-esophageal-cancer/
https://ascopost.com/issues/september-25-2021/guideline-rapid-update-provides-new-direction-on-the-care-of-patients-with-residual-disease-in-locally-advanced-esophageal-cancer/
https://www.ascopost.com/issues/september-25-2021/nivolumab-plus-chemotherapy-improves-survival-in-advanced-gastric-and-esophageal-adenocarcinomas-now-to-figure-out-the-details-in-these-heterogeneous-diseases/
https://ascopost.com/issues/september-25-2021/nivolumab-plus-chemotherapy-improves-survival-in-advanced-gastric-and-esophageal-adenocarcinomas-now-to-figure-out-the-details-in-these-heterogeneous-diseases/
https://www.ascopost.com/issues/september-25-2021/adding-first-line-nivolumab-to-chemotherapy-improves-survival-in-gastric-gastroesophageal-junction-and-esophageal-adenocarcinomas/
https://ascopost.com/issues/september-25-2021/adding-first-line-nivolumab-to-chemotherapy-improves-survival-in-gastric-gastroesophageal-junction-and-esophageal-adenocarcinomas/
https://www.ascopost.com/videos/esmo-congress-2021/naveen-vasudev-on-rcc-changing-the-dosing-schedule-of-ipilimumab-plus-nivolumab/
https://ascopost.com/videos/esmo-congress-2021/naveen-vasudev-on-rcc-changing-the-dosing-schedule-of-ipilimumab-plus-nivolumab/
https://www.ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/epov-mansoor-raza-mirza/
https://ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/epov-mansoor-raza-mirza/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/highlights-from-the-2021-asco-annual-meeting/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/highlights-from-the-2021-asco-annual-meeting/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-jason-j-luke/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-jason-j-luke/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/targeting-lag-3-and-pd-1-with-relatlimab-and-nivolumab-a-new-option-under-study-in-advanced-melanoma/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/targeting-lag-3-and-pd-1-with-relatlimab-and-nivolumab-a-new-option-under-study-in-advanced-melanoma/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-rana-r-mckay/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-rana-r-mckay/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-david-cunningham/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-david-cunningham/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-anthony-tc-chan/
https://ascopost.com/issues/september-10-2021-supplement-asco-highlights/epov-anthony-tc-chan/
https://www.ascopost.com/news/september-2021/nivolumab-vs-gemcitabine-or-pegylated-liposomal-doxorubicin-what-regimen-improves-survival-in-platinum-resistant-ovarian-cancer/
https://ascopost.com/news/september-2021/nivolumab-vs-gemcitabine-or-pegylated-liposomal-doxorubicin-what-regimen-improves-survival-in-platinum-resistant-ovarian-cancer/
https://www.ascopost.com/news/september-2021/several-studies-show-rovalpituzumab-tesirine-is-ineffective-against-sclc/
https://ascopost.com/news/september-2021/several-studies-show-rovalpituzumab-tesirine-is-ineffective-against-sclc/
https://www.ascopost.com/issues/september-10-2021/are-triplets-necessary-for-braf-mutated-melanoma/
https://ascopost.com/issues/september-10-2021/are-triplets-necessary-for-braf-mutated-melanoma/
https://www.ascopost.com/news/august-2021/patients-with-melanoma-previously-treated-with-pd-1-or-mapk-inhibitors-may-be-less-likely-to-respond-to-act-til-therapy/
https://ascopost.com/news/august-2021/patients-with-melanoma-previously-treated-with-pd-1-or-mapk-inhibitors-may-be-less-likely-to-respond-to-act-til-therapy/
https://www.ascopost.com/issues/september-10-2021/fda-approves-nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://ascopost.com/issues/september-10-2021/fda-approves-nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://www.ascopost.com/news/august-2021/small-study-evaluates-combination-ipilimumabnivolumab-in-patients-with-angiosarcoma/
https://ascopost.com/news/august-2021/small-study-evaluates-combination-ipilimumabnivolumab-in-patients-with-angiosarcoma/
https://www.ascopost.com/videos/2021-pan-pacific-lymphoma-conference/james-armitage-on-advanced-hodgkin-lymphoma-choosing-among-beacopp-a-avd-and-checkpoint-inhibitors/
https://ascopost.com/videos/2021-pan-pacific-lymphoma-conference/james-armitage-on-advanced-hodgkin-lymphoma-choosing-among-beacopp-a-avd-and-checkpoint-inhibitors/
https://www.ascopost.com/issues/august-25-2021/tackling-the-challenge-of-pancreatic-cancer-new-approaches/
https://ascopost.com/issues/august-25-2021/tackling-the-challenge-of-pancreatic-cancer-new-approaches/
https://www.ascopost.com/issues/august-10-2021/javelin-head-and-neck-100-trial-when-failure-seems-fatal-hope-is-not-lost/
https://ascopost.com/issues/august-10-2021/javelin-head-and-neck-100-trial-when-failure-seems-fatal-hope-is-not-lost/
https://www.ascopost.com/issues/august-10-2021/epov-kei-muro/
https://ascopost.com/issues/august-10-2021/epov-kei-muro/
https://www.ascopost.com/news/august-2021/adjuvant-nivolumab-improves-disease-free-survival-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://ascopost.com/news/august-2021/adjuvant-nivolumab-improves-disease-free-survival-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://www.ascopost.com/issues/august-10-2021/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-is-disease-free-survival-the-best-endpoint/
https://ascopost.com/issues/august-10-2021/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-is-disease-free-survival-the-best-endpoint/
https://www.ascopost.com/issues/august-10-2021/adjuvant-nivolumab-improves-disease-free-survival-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://ascopost.com/issues/august-10-2021/adjuvant-nivolumab-improves-disease-free-survival-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://www.ascopost.com/news/august-2021/neoadjuvant-cabozantinibnivolumab-may-make-resection-possible-for-some-patients-with-liver-cancer/
https://ascopost.com/news/august-2021/neoadjuvant-cabozantinibnivolumab-may-make-resection-possible-for-some-patients-with-liver-cancer/
https://www.ascopost.com/issues/july-25-2021/benefits-of-adjuvant-pembrolizumab-in-melanoma-reinforced-by-eortc-1325keynote-054-updates/
https://ascopost.com/issues/july-25-2021/benefits-of-adjuvant-pembrolizumab-in-melanoma-reinforced-by-eortc-1325keynote-054-updates/
https://www.ascopost.com/news/july-2021/addition-of-ipilimumab-to-nivolumab-in-previously-treated-immunotherapy-naive-stage-iv-squamous-nsclc/
https://ascopost.com/news/july-2021/addition-of-ipilimumab-to-nivolumab-in-previously-treated-immunotherapy-naive-stage-iv-squamous-nsclc/
https://www.ascopost.com/news/july-2021/interleukin-2-pathway-agonist-bempegaldesleukin-plus-nivolumab-in-the-first-line-treatment-of-metastatic-melanoma/
https://ascopost.com/news/july-2021/interleukin-2-pathway-agonist-bempegaldesleukin-plus-nivolumab-in-the-first-line-treatment-of-metastatic-melanoma/
https://www.ascopost.com/issues/july-10-2021/epov-jason-luke/
https://ascopost.com/issues/july-10-2021/epov-jason-luke/
https://www.ascopost.com/issues/august-10-2021/nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/
https://ascopost.com/issues/august-10-2021/nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/
https://www.ascopost.com/issues/july-10-2021/a-shift-in-the-treatment-of-advanced-melanoma/
https://ascopost.com/issues/july-10-2021/a-shift-in-the-treatment-of-advanced-melanoma/
https://www.ascopost.com/issues/july-10-2021/responses-to-pembrolizumab-and-ipilimumab-after-anti-pd-1l1-failure-in-advanced-melanoma/
https://ascopost.com/issues/july-10-2021/responses-to-pembrolizumab-and-ipilimumab-after-anti-pd-1l1-failure-in-advanced-melanoma/
https://www.ascopost.com/issues/june-25-2021/epov-rui-hua-xu/
https://ascopost.com/issues/june-25-2021/epov-rui-hua-xu/
https://www.ascopost.com/issues/june-25-2021/checkmate-648-first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-25-2021/checkmate-648-first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/issues/june-25-2021/epov-rana-r-mckay/
https://ascopost.com/issues/june-25-2021/epov-rana-r-mckay/
https://www.ascopost.com/videos/2021-asco-annual-meeting/martin-reck-on-nsclc-nivolumab-ipilimumab-and-chemotherapy-for-advanced-disease/
https://ascopost.com/videos/2021-asco-annual-meeting/martin-reck-on-nsclc-nivolumab-ipilimumab-and-chemotherapy-for-advanced-disease/
https://www.ascopost.com/videos/2021-asco-annual-meeting/matt-galsky-on-bladder-cancer-neoadjuvant-therapy-with-gemcitabine-cisplatin-and-nivolumab/
https://ascopost.com/videos/2021-asco-annual-meeting/matt-galsky-on-bladder-cancer-neoadjuvant-therapy-with-gemcitabine-cisplatin-and-nivolumab/
https://www.ascopost.com/news/june-2021/addition-of-first-line-nivolumab-to-chemotherapy-in-advanced-gastric-cancers-checkmate-649/
https://ascopost.com/news/june-2021/addition-of-first-line-nivolumab-to-chemotherapy-in-advanced-gastric-cancers-checkmate-649/
https://www.ascopost.com/news/june-2021/epov-anthony-tc-chan/
https://ascopost.com/news/june-2021/epov-anthony-tc-chan/
https://www.ascopost.com/issues/june-25-2021/epov-mansoor-raza-mirza/
https://ascopost.com/issues/june-25-2021/epov-mansoor-raza-mirza/
https://www.ascopost.com/issues/june-10-2021/dual-immune-checkpoint-blockade-with-nivolumab-and-ipilimumab-for-treatment-of-malignant-pleural-mesothelioma/
https://ascopost.com/issues/june-10-2021/dual-immune-checkpoint-blockade-with-nivolumab-and-ipilimumab-for-treatment-of-malignant-pleural-mesothelioma/
https://www.ascopost.com/issues/june-10-2021/nivolumabipilimumab-improves-overall-survival-vs-chemotherapy-in-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma/
https://ascopost.com/issues/june-10-2021/nivolumabipilimumab-improves-overall-survival-vs-chemotherapy-in-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma/
https://www.ascopost.com/issues/june-10-2021/disease-free-survival-benefit-with-adjuvant-immunotherapy-in-resectable-esophageal-cancer-practice-changing-for-all-patients/
https://ascopost.com/issues/june-10-2021/disease-free-survival-benefit-with-adjuvant-immunotherapy-in-resectable-esophageal-cancer-practice-changing-for-all-patients/
https://www.ascopost.com/issues/june-10-2021/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/
https://ascopost.com/issues/june-10-2021/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/